# Docking Screen

High-throughput molecular docking campaigns for virtual screening, lead optimization, and structure-based drug discovery in aging therapeutics.

## Agents Used

This command leverages the **Drug Discovery Analyst** and **Proteomics Analyst** agents for docking analysis.

## Description

Performs large-scale molecular docking campaigns screening compound libraries against protein targets. Implements protein preparation, ligand preparation, docking simulations, scoring and ranking, binding mode analysis, and structure-activity relationship interpretation. Essential for virtual screening of senolytics, geroprotectors, and pathway modulators.

## Usage

```
/docking-screen
```

After invoking the command, provide:
- Target protein structure(s)
- Compound library for screening
- Binding site definition
- Screening parameters and priorities

## Inputs

**Required:**
- Protein structure: PDB file or predicted structure
- Compound library: SMILES, SDF, or mol2 format
- Binding site: Coordinates or residue list

**Optional:**
- Known actives: For method validation
- Pharmacophore constraints: Required interactions
- Flexible residues: For induced fit
- Water molecules: To keep in binding site

## Process

The command performs:

1. **Protein preparation**: Structure cleanup and optimization
2. **Binding site analysis**: Characterizes pocket properties
3. **Ligand preparation**: 3D conformers and protonation
4. **Grid generation**: Defines docking space
5. **Docking simulation**: Samples binding poses
6. **Scoring**: Ranks compounds by predicted affinity
7. **Pose analysis**: Characterizes binding modes
8. **Hit selection**: Prioritizes compounds for testing

## Outputs

**Docking scores:**
- Ranked compound list
- Predicted binding affinities
- Scoring function values
- Relative rankings

**Binding poses:**
- 3D coordinates of docked compounds
- Protein-ligand complexes
- Multiple poses per compound
- Clustering of similar poses

**Interaction analysis:**
- Hydrogen bonds
- Hydrophobic contacts
- Pi-pi interactions
- Salt bridges
- Metal coordination

**Binding site analysis:**
- Pocket volume and shape
- Hydrophobicity
- Electrostatic potential
- Druggability assessment

**Structure-activity relationships:**
- Scaffold analysis
- Pharmacophore models
- Key interaction patterns
- Optimization suggestions

**Hit prioritization:**
- Top-ranked compounds
- Diversity selection
- Drug-like property filtering
- Synthetic accessibility

## Interpretation Guidelines

The command provides:
- Virtual screening hit lists
- Predicted binding modes
- Key interactions for activity
- Optimization strategies

For aging research specifically:
- Senolytic target docking
- Longevity pathway inhibitors
- Anti-inflammatory compound screening
- Mitochondrial target docking

## Example Use Cases

**Senolytic screening:**
Dock compound libraries against BCL-2 family proteins identifying selective senolytic candidates.

**SASP modulator discovery:**
Screen for compounds inhibiting inflammatory signaling targets like NF-κB.

**Mitophagy enhancers:**
Identify compounds activating mitophagy pathways through target protein binding.

**mTOR pathway modulators:**
Virtual screen for novel rapamycin-like compounds or pathway inhibitors.

## Integration with Other Commands

Results complement:
- `/predict-protein-structure` provides target structures
- `/senolytic-discovery-pipeline` uses docking as screening step
- `/pathway-enrichment` interprets target pathway context
- `/analyze-ptm` identifies PTM sites affecting binding

## Best Practices

**Protein preparation:**
- Add missing atoms and hydrogens
- Optimize hydrogen bonds
- Check protonation states
- Validate structure quality

**Binding site selection:**
- Use known ligand positions if available
- Validate pocket druggability
- Consider allosteric sites
- Account for flexibility

**Docking validation:**
- Redock known ligands
- Check pose reproduction
- Validate with experimental data
- Test multiple scoring functions

**Hit selection:**
- Don't rely solely on scores
- Inspect binding modes manually
- Consider drug-like properties
- Prioritize diverse scaffolds

## Technical Notes

Implements multiple docking programs (AutoDock Vina, GOLD, Glide, DOCK) with appropriate scoring functions. Handles protein flexibility through ensemble docking or induced fit protocols. Applies consensus scoring combining multiple functions.

For aging targets, recognizes unique binding pockets in longevity pathway proteins and considers selectivity requirements for chronic administration.

## Docking Algorithms

**Grid-based:**
AutoDock, Vina. Fast by pre-computing interaction grids. Good for large screens.

**Shape-matching:**
DOCK. Matches ligand shape to pocket. Effective for fragment screening.

**Genetic algorithms:**
GOLD, AutoDock. Explore conformational space effectively. Slower but thorough.

**Incremental construction:**
FlexX. Builds ligand incrementally in pocket. Good for flexible ligands.

## Scoring Functions

**Force field-based:**
Classical mechanics potential energy. Physically motivated but computationally expensive.

**Empirical:**
Weighted terms for different interactions. Fast and widely used (Vina, GOLD).

**Knowledge-based:**
Statistical potentials from known structures. Complement other methods.

**Machine learning:**
Trained on experimental binding data. Improving rapidly with deep learning.

**Consensus scoring:**
Combines multiple functions improving enrichment over single methods.

## Protein Flexibility

**Rigid docking:**
Protein fixed during docking. Fast but misses induced fit.

**Soft docking:**
Relaxed steric clashes allowing overlap. Pseudo-flexibility without computation cost.

**Flexible sidechains:**
Allows key residues to move. Balances accuracy and speed.

**Ensemble docking:**
Docks to multiple protein conformations. Captures conformational heterogeneity.

**Induced fit:**
Refines protein around docked ligand. Most accurate but expensive.

## Binding Site Analysis

**Druggability:**
Assesses whether pocket is suitable for drug-like molecules. Deep, enclosed pockets preferred.

**Hot spots:**
Residues contributing most to binding. Target these in optimization.

**Cryptic pockets:**
Transient pockets not visible in apo structure. Require MD or experimental structures.

**Allosteric sites:**
Non-active site pockets offering selectivity. Increasingly important targets.

## Virtual Screening

**Library selection:**
- Diverse for hit identification
- Focused for optimization
- Fragment libraries for FBDD
- Natural product-inspired for novel scaffolds

**Filtering:**
Apply drug-like filters before docking reducing library size.

**Consensus docking:**
Dock with multiple programs, select consensus hits.

**Hierarchical screening:**
Fast docking initially, more rigorous for top hits.

## Aging-Specific Targets

**Senescence targets:**
BCL-2 family (BCL-2, BCL-xL, BCL-W) for senolytics. Selectivity critical.

**SASP targets:**
NF-κB, p38 MAPK, IL-1 receptors for SASP suppression.

**Longevity pathways:**
mTOR, AMPK, sirtuins, IGF-1R for pathway modulation.

**Mitochondrial targets:**
Complex I, mitophagy proteins, UCP proteins.

**DNA damage:**
PARP, ATM, ATR for DNA repair modulation.

## Structure-Activity Relationships

**Scaffold hopping:**
Find alternative cores with similar activity. Expands chemical space.

**R-group analysis:**
Systematic variation of substituents identifying optimal modifications.

**Bioisosteres:**
Replace functional groups with similar properties improving pharmacokinetics.

**Pharmacophore refinement:**
Essential features for activity guide optimization.

## Selectivity Prediction

**Off-target docking:**
Dock against related proteins assessing selectivity.

**Family-wide screening:**
Screen all family members simultaneously.

**Key residue analysis:**
Exploit differences in binding pockets for selectivity.

**Structural alignment:**
Compare target to off-targets identifying selectivity determinants.

## Limitations

- Scoring functions imperfect for ranking
- Protein flexibility not fully captured
- Solvation effects approximated
- Cannot predict all binding modes
- Experimental validation essential

Docking enriches actives but doesn't guarantee success. Use as prioritization tool.

## Advanced Features

**Covalent docking:**
Models covalent bond formation with target residues.

**Metal coordination:**
Handles metal-ligand coordination properly.

**Peptide docking:**
Specialized methods for peptide ligands with more flexibility.

**Fragment docking:**
Screens small fragments for FBDD campaigns.

**Water-mediated:**
Keeps bridging water molecules in binding site.

## Experimental Validation

**Biochemical assays:**
Confirm binding and activity in vitro.

**Biophysical methods:**
SPR, ITC, MST validate binding directly.

**Crystal structures:**
Co-crystal structures confirm predicted binding modes.

**Cell-based assays:**
Test function in cellular context.

**In vivo validation:**
Animal studies for lead compounds.

## Optimization Strategies

**Grow into pockets:**
Extend compounds to fill unoccupied space.

**Rigidify:**
Reduce entropy loss on binding improving affinity.

**Optimize interactions:**
Add or modify groups improving key interactions.

**Improve selectivity:**
Exploit pocket differences for selectivity.

**Drug-like properties:**
Maintain or improve ADMET while optimizing potency.

## Computational Efficiency

**Parallelization:**
Distribute docking across compute nodes.

**GPU acceleration:**
Some programs leverage GPUs for speed.

**Smart filtering:**
Pre-filter libraries reducing compounds to dock.

**Tiered approach:**
Fast initial screen, rigorous for top hits.

---

This command enables high-throughput virtual screening identifying compound starting points for aging therapeutic development and guiding structure-based optimization of senolytic and geroprotector candidates.